glp-1 clinical studies Changes in weight with RAs in head-to-head studies. *p < The cardiovascular effects of GLP-1

Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes

Understanding this mechanism helps explain both why it works so effectively and why certain female-specific considerations matter

Sources Eli Lilly press release TRIUMPH-1 Phase 3 topline results, May 21, 2026 Eli Lilly press release TRIUMPH-4 Phase 3 trial results, December 2025 Eli Lilly press release TRANSCEND-T2D-1 topline results, March 19, 2026 Bajaj HS et al

BMI 40.0 and above (class III obesity)

PubMed, Kadri, Selma Imamovi, et al

Smart Ways Women Can Manage GLP-1 Side Effects Managing side effects doesnt mean stopping the medicationit means optimizing how your body adapts to it